{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/COGT/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-18T16:01:22.812Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9112,"canonical_name":"Cogent Biosciences, Inc.","cik":"0001622229","uei":null,"lei":null,"duns":null,"ticker":"COGT"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":15,"clinical":3},"count":18,"timeline":[{"ts":"2026-09-02","kind":"sec.filing","form_type":"8-K","title":"8-K — Cogent Biosciences, Inc. — 2026-09-02","url_slug":"/sec/cik-0001622229/8-k/0001193125-26-380194","accession_number":"0001193125-26-380194","importance":35},{"ts":"2026-08-10","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Cogent Biosciences, Inc. — 2026-08-10","url_slug":"/sec/cik-0001622229/10-q/0001193125-26-342393","accession_number":"0001193125-26-342393","importance":45},{"ts":"2026-08-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Cogent Biosciences, Inc. — 2026-08-10","url_slug":"/sec/cik-0001622229/8-k/0001193125-26-341315","accession_number":"0001193125-26-341315","importance":35},{"ts":"2026-08-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Cogent Biosciences, Inc. — 2026-08-10","url_slug":"/sec/cik-0001622229/8-k/0001193125-26-342695","accession_number":"0001193125-26-342695","importance":35},{"ts":"2026-08-10","kind":"sec.filing","form_type":"424B5","title":"424B5 — Cogent Biosciences, Inc. — 2026-08-10","url_slug":"/sec/cik-0001622229/424b5/0001193125-26-342683","accession_number":"0001193125-26-342683","importance":30},{"ts":"2026-07-31","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Cogent Biosciences, Inc. — 2026-07-31","url_slug":"/sec/cik-0001622229/schedule-13g/0002100119-26-001323","accession_number":"0002100119-26-001323","importance":55},{"ts":"2026-07-27","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Cogent Biosciences, Inc. — 2026-07-27","url_slug":"/sec/cik-0001622229/schedule-13g-a/0002012383-26-002235","accession_number":"0002012383-26-002235","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Cogent Biosciences, Inc. — 2026-06-11","url_slug":"/sec/cik-0001622229/8-k/0001193125-26-267566","accession_number":"0001193125-26-267566","importance":35},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — Cogent Biosciences, Inc. — 2026-06-11","url_slug":"/sec/cik-0001622229/4/0001193125-26-267665","accession_number":"0001193125-26-267665","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — Cogent Biosciences, Inc. — 2026-06-11","url_slug":"/sec/cik-0001622229/4/0001193125-26-267666","accession_number":"0001193125-26-267666","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — Cogent Biosciences, Inc. — 2026-06-11","url_slug":"/sec/cik-0001622229/4/0001193125-26-267670","accession_number":"0001193125-26-267670","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — Cogent Biosciences, Inc. — 2026-06-11","url_slug":"/sec/cik-0001622229/4/0001193125-26-267662","accession_number":"0001193125-26-267662","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — Robbins Andrew R — 2026-05-21","url_slug":"/sec/cik-0001590157/4/0001193125-26-234578","accession_number":"0001193125-26-234578","importance":30},{"ts":"2026-05-19","kind":"sec.insider.g","reporter":"Robbins Andrew R","title":"President and CEO","shares":160000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.insider.g","reporter":"Robbins Andrew R","title":"President and CEO","shares":160000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Cogent Biosciences, Inc.","title":"Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors","security_title":null,"status":"AVAILABLE","accession_number":"NCT06948955","excerpt":"[\"Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors\"]","importance":25},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Cogent Biosciences, Inc.","title":"Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis","security_title":null,"status":"AVAILABLE","accession_number":"NCT06915766","excerpt":"[\"Systemic Mastocytoses, Indolent\",\"Systemic Mastocytoses, Aggressive\"]","importance":25},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Cogent Biosciences, Inc.","title":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT04996875","excerpt":"[\"Advanced Systemic Mastocytosis (AdvSM)\",\"SM With an Associated Hematologic Neoplasm (SM-AHN)\",\"Mast Cell Leukemia (MCL)\",\"Aggressive Systemic Mastocytosis (ASM)\"]","importance":45}]}